S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
NAMS · NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
NewAmsterdam Pharma Company NV (NAMS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$21.52
+0.02
(+0.07%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$21.52
$21.31
$22.26
52-WEEK RANGE
$21.52
$19.58
$42.20
What's happening
- NAMS is up 0.07% today, trading at $21.52. — Live quote
- Volume today (75,336) is well below its 3-month average of 1,301,290. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (before market open), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.52 actual vs. $-0.50 estimated (-4.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 12
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (23 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NAMS
-38.71%
vs S&P 500
-51.49%
1-YEAR RETURN
NAMS
-42.91%
vs S&P 500
-57.47%
6-MONTH RETURN
NAMS
-35.24%
3-MONTH RETURN
NAMS
-33.52%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.52
Est. $-0.50
MISS -4.4%
2026-04-26 (Q1 2026)
$-0.40
Est. $-0.50
BEAT +20.3%
2026-01-26 (Q4 2025)
$-0.62
Est. $-0.39
MISS -57.8%
2025-10-26 (Q3 2025)
$-0.61
Est. $-0.40
MISS -51.0%
Valuation Measures & Ratios
Enterprise Value4$2.15B
Forward P/E5—
PEG Ratio6-0.28
Price / Sales (TTM1)360.91
Price / Book76.27
EV4 / Revenue301.35
EV4 / EBITDA—
Profit Margin-3644.21%
Operating Margin-3432.20%
Return on Equity (ROE8)-38.33%
Return on Assets (ROA9)-34.68%
Avg Volume (3M)1,301,290
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $4.18B | $3.88B | $3.35B | $2.10B | $2.38B |
| P/E | -20.72 | -21.85 | -23.01 | -18.65 | -12.59 |
| Price/Sales | 159.47 | 151.91 | 64.92 | 39.22 | 66.53 |
| Price/Book | 6.63 | 5.83 | 4.60 | 2.70 | 3.06 |
| EV/Revenue | 143.30 | 133.97 | 54.48 | 28.68 | 45.61 |
| EV/EBITDA | -17.58 | -15.68 | -15.23 | — | — |
| ROE | -31.98% | -26.66% | -19.99% | -14.46% | -24.31% |
| ROA | -28.67% | -24.21% | -18.51% | -13.81% | -23.09% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short19,045,378
Change from Prior Settlement+21.61%
% of Float—
Days to Cover (Short Ratio)9.39
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -80.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -3644.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -42.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NAMS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | $3.0M | $348.0K | $19.1M | $3.0M | $29.1M | $2.3M | $1.4M |
| Operating income | -$64.9M | -$58.4M | -$55.1M | -$35.6M | -$68.9M | -$25.0M | -$52.6M | -$55.5M |
| Net income | -$64.1M | -$48.4M | -$72.0M | -$17.4M | -$39.5M | -$16.6M | -$39.0M | -$93.8M |
| EPS (diluted) | $-0.52 | $-0.40 | $-0.61 | $-0.15 | $-0.34 | $-0.18 | $-0.41 | $-1.06 |
| EPS (basic) | $-0.52 | $-0.40 | $-0.61 | $-0.15 | $-0.34 | $-0.18 | $-0.41 | $-1.06 |
| Operating margin | -$1.8K | -$1.9K | -$15.8K | -$186 | -$2.3K | -$86 | -$2.3K | -$4.0K |
| Net margin | -$1.7K | -$1.6K | -$20.7K | -$91 | -$1.3K | -$57 | -$1.7K | -$6.7K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $704.5M | $732.6M | $769.3M | $786.4M | $815.1M | $818.4M | $864.6M | $439.2M |
| Total liabilities | $73.0M | $67.4M | $85.9M | $58.4M | $36.6M | $41.0M | $107.1M | $60.3M |
| Stockholders' equity | $631.4M | $665.2M | $683.4M | $728.1M | $778.5M | $777.4M | $757.5M | $378.9M |
| Total current assets | $659.2M | $658.0M | $675.7M | $732.3M | $769.9M | $817.3M | $863.4M | $437.9M |
| Total current liabilities | $73.0M | $67.4M | $85.8M | $58.3M | $36.5M | $40.9M | $106.9M | $41.3M |
| Cash & equivalents | $424.2M | $457.6M | $490.0M | $538.4M | $563.9M | $748.4M | $771.7M | $422.7M |
| Marketable securities (current) | $209.7M | $178.5M | $146.2M | $164.5M | $175.3M | $60.1M | $62.4M | — |
| Marketable securities (non-current) | $44.4M | $71.2M | $92.6M | $53.1M | $44.2M | — | — | — |
| Property, plant & equipment | $411.0K | $379.0K | $383.0K | $323.0K | $312.0K | $238.0K | $242.0K | $231.0K |
| Accounts payable | $5.4M | $8.1M | $9.0M | $3.6M | $5.9M | $6.1M | $4.7M | $7.0M |
| Deferred revenue (current) | $2.8M | $4.0M | $4.0M | — | — | $3.0M | $6.0M | $4.5M |
| Common stock & paid-in capital | $14.7M | $14.6M | $14.3M | $14.1M | $14.0M | $14.0M | $13.4M | $11.4M |
| Retained earnings | -$875.0M | -$810.8M | -$762.4M | -$687.5M | -$615.5M | -$598.1M | -$558.6M | -$466.4M |
| Accumulated other comprehensive income (loss) | $3.9M | $4.2M | $4.8M | $4.6M | $4.3M | $4.4M | $4.5M | $4.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.2M | -$30.6M | -$40.9M | -$32.8M | -$37.7M | -$36.5M | -$37.5M | -$12.5M |
| Investing cash flow | -$4.8M | -$11.5M | -$21.1M | $2.5M | -$159.1M | $2.9M | -$62.2M | -$75.0K |
| Financing cash flow | $11.0M | $11.1M | $13.7M | $5.9M | $3.4M | $6.5M | $456.6M | $58.0K |
| Depreciation & amortization | $59.0K | $62.0K | $59.0K | $64.0K | $45.0K | $52.0K | $51.0K | $28.0K |
| Share-based compensation | $18.4M | $18.0M | $14.0M | $15.0M | $15.2M | $15.2M | $9.4M | $8.0M |
| Change in accounts payable | -$2.7M | -$793.0K | $5.3M | -$2.3M | -$391.0K | $2.3M | -$3.2M | $1.9M |
| Purchases of investments | $51.2M | $62.5M | $71.5M | $31.9M | $183.7M | $9.6M | $62.2M | — |
| Tax withholding on stock comp | — | — | — | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M | -$35.0M |
| Net income | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M |
| EPS (diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 |
| EPS (basic) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 |
| Operating margin | -$1.0K | -$387 | -$1.3K | -$3 | — |
| Net margin | -$906 | -$530 | -$1.3K | -$22 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M | — |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M | — |
| Stockholders' equity | $683.4M | $757.5M | $288.4M | $430.1M | -$113.8M |
| Total current assets | $675.7M | $863.4M | $346.8M | $478.0M | — |
| Total current liabilities | $85.8M | $106.9M | $49.9M | $36.1M | — |
| Cash & equivalents | $490.0M | $771.7M | $340.4M | — | — |
| Marketable securities (current) | $146.2M | $62.4M | — | — | — |
| Marketable securities (non-current) | $92.6M | — | — | — | — |
| Property, plant & equipment | $383.0K | $242.0K | $46.0K | $34.0K | — |
| Accounts payable | $9.0M | $4.7M | $16.9M | $11.9M | — |
| Deferred revenue (current) | $4.0M | $6.0M | $8.9M | $13.9M | — |
| Common stock & paid-in capital | $14.3M | $13.4M | $10.2M | $10.1M | — |
| Retained earnings | -$762.4M | -$558.6M | -$317.0M | -$140.0M | — |
| Accumulated other comprehensive income (loss) | $4.8M | $4.5M | $4.4M | $4.4M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | $10.7M | -$29.5M |
| Investing cash flow | -$174.9M | -$62.8M | -$24.0K | -$221.0K | -$24.0K |
| Financing cash flow | $29.5M | $659.5M | $8.9M | $391.9M | $84.7M |
| Depreciation & amortization | $220.0K | $113.0K | $49.0K | $9.0K | $5.0K |
| Share-based compensation | $59.4M | $33.6M | $24.6M | $4.1M | $1.2M |
| Change in accounts payable | $4.9M | -$12.9M | $5.1M | $4.8M | $6.6M |
| Purchases of investments | $296.7M | $62.2M | — | — | — |
| Tax withholding on stock comp | — | $989.0K | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NAMS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers85.0%
Shares Outstanding123,370,232
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18,088,902 | $613.0M | 14.66% | +6.8% | 2026-08-14 |
| Capital World Investors | 12,230,557 | $414.5M | 9.91% | +10.1% | 2026-08-07 |
| FMR LLC | 10,339,663 | $350.4M | 8.38% | +18.0% | 2026-08-13 |
| RA CAPITAL MANAGEMENT, L.P. | 9,550,191 | $323.7M | 7.74% | +0.0% | 2026-08-14 |
| FCPM III SERVICES B.V. | 8,490,353 | $287.7M | 6.88% | -7.7% | 2026-08-14 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 4,264,789 | $144.5M | 3.46% | +0.0% | 2026-08-14 |
| VIKING GLOBAL INVESTORS LP | 4,203,567 | $142.5M | 3.41% | +0.0% | 2026-08-14 |
| Bain Capital Life Sciences Investors, LLC | 3,806,566 | $129.0M | 3.09% | -47.9% | 2026-08-14 |
| MAVERICK CAPITAL LTD | 3,267,802 | $110.7M | 2.65% | +49.5% | 2026-08-14 |
| Duquesne Family Office LLC | 3,070,146 | $104.0K | 2.49% | +0.0% | 2026-08-14 |
| Jupiter Topco LLC | 2,535,682 | $86.0M | 2.06% | +0.0% | 2026-08-14 |
| Medicxi Ventures Management (Jersey) Ltd | 2,208,639 | $74.9M | 1.79% | -17.4% | 2026-08-04 |
| JENNISON ASSOCIATES LLC | 2,102,286 | $71.2M | 1.70% | -23.6% | 2026-08-03 |
| Orbis Allan Gray Ltd | 1,747,627 | $59.2M | 1.42% | +0.0% | 2026-08-14 |
| Polar Capital Holdings Plc | 1,724,518 | $58.4M | 1.40% | -39.1% | 2026-08-14 |
| Capital International Investors | 1,723,495 | $58.4M | 1.40% | +19.6% | 2026-08-07 |
| Goldman Sachs Group Inc | 1,544,911 | $52.4M | 1.25% | -20.6% | 2026-08-14 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1,536,472 | $52.1M | 1.25% | -30.3% | 2026-08-12 |
| Castle Hook Partners LP | 1,371,005 | $46.5M | 1.11% | +31.5% | 2026-08-14 |
| ALLIANCEBERNSTEIN L.P. | 1,259,940 | $40.3M | 1.02% | +5.1% | 2026-08-14 |
| Ameriprise Financial Inc | 1,253,549 | $42.5M | 1.02% | +66.5% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,167,357 | $39.6K | 0.95% | +0.0% | 2026-08-14 |
| Jpmorgan Chase & Co | 1,132,955 | $38.4M | 0.92% | +28.1% | 2026-08-12 |
| Aberdeen Group plc | 1,102,785 | $37.4M | 0.89% | +31.8% | 2026-07-31 |
| BlackRock, Inc. | 1,063,750 | $36.1M | 0.86% | +20.0% | 2026-08-07 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-05 to 2026-09-30
Recent transactions
- Insiders have net sold 376,846 shares over the last 182 days, across 1 purchase and 9 sales.
- Most recent: Kastelein Johannes Jacob Pieter (Chief Scientific Officer) — Option exercise of 50,246 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)10,000 sh(1 txns)
Sales (open market)386,846 sh(9 txns)
Net Shares-376,846
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Option exercise | 2026-09-30 | 50,246 |
| Davidson Michael H. | Chief Executive Officer | Open market purchase | 2026-09-14 | 10,000 |
| Smither John W | Reporting person | Open market sale | 2026-09-04 | 1,600 |
| Gunning Robert William | Vice President, Controller | Grant / award | 2026-09-01 | 3,200 |
| Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 2026-07-20 | 25,000 |
| LANGE LOUIS G | Reporting person | Open market sale | 2026-03-11 | 44,173 |
| Somaiya Mayur Ian | Chief Financial Officer | Option exercise | 2026-01-21 | 39,784 |
| van der Kamp Hilde Johanna | Reporting person | Grant / award | 2026-01-07 | 3,400 |
| Gulfo Adele M. | Reporting person | Grant / award | 2026-01-07 | 3,400 |
| Lewis William | Reporting person | Grant / award | 2026-01-07 | 3,400 |
| McKenna Mark C. | Reporting person | Grant / award | 2026-01-07 | 3,400 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Option exercise | 50,246 | — |
| 2026-09-30 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 50,246 | $25.03 |
| 2026-09-14 | Davidson Michael H. | Chief Executive Officer | Open market purchase | 10,000 | $22.65 |
| 2026-09-04 | Smither John W | Reporting person | Open market sale | 1,600 | $25.32 |
| 2026-09-01 | Gunning Robert William | Vice President, Controller | Grant / award | 3,200 | $0.00 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Option exercise | 125,000 | — |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 125,000 | $26.91 |
| 2026-07-20 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 25,000 | $11.90 |
| 2026-07-20 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 80,000 | $11.17 |
| 2026-07-20 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 70,200 | $29.96 |
| 2026-07-20 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 31,885 | $31.05 |
| 2026-07-20 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 2,915 | $31.71 |
| 2026-06-22 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 25,000 | $10.90 |
| 2026-06-22 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 15,000 | $11.90 |
| 2026-06-22 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 39,700 | $30.20 |
| 2026-06-22 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 300 | $30.73 |
| 2026-05-26 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 60,000 | $10.00 |
| 2026-05-26 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 5,000 | $10.90 |
| 2026-05-26 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 65,000 | $35.69 |
| 2026-03-11 | LANGE LOUIS G | Reporting person | Open market sale | 44,173 | $30.41 |
| 2026-03-11 | LANGE LOUIS G | Reporting person | Open market sale | 446 | $31.23 |
| 2026-03-09 | LANGE LOUIS G | Reporting person | In-the-money option exercise | 44,619 | $11.50 |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Option exercise | 101,409 | — |
| 2026-03-09 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 101,409 | $30.29 |
| 2026-03-06 | LANGE LOUIS G | Reporting person | Open market sale | 28,186 | $29.41 |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Option exercise | 94,124 | — |
| 2026-03-06 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 94,124 | $30.32 |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Option exercise | 104,467 | — |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 104,467 | $30.30 |
| 2026-03-02 | Davidson Michael H. | Chief Executive Officer | Option exercise | 443,707 | — |
| 2026-03-02 | Davidson Michael H. | Chief Executive Officer | Open market sale | 443,707 | $33.25 |
| 2026-02-26 | Davidson Michael H. | Chief Executive Officer | Option exercise | 183,332 | — |
| 2026-02-26 | Davidson Michael H. | Chief Executive Officer | Open market sale | 165,408 | $33.63 |
| 2026-02-26 | Davidson Michael H. | Chief Executive Officer | Open market sale | 17,924 | $34.44 |
| 2026-02-25 | Davidson Michael H. | Chief Executive Officer | Option exercise | 58,253 | — |
| 2026-02-25 | Davidson Michael H. | Chief Executive Officer | Open market sale | 46,517 | $35.11 |
| 2026-02-25 | Davidson Michael H. | Chief Executive Officer | Open market sale | 10,436 | $35.96 |
| 2026-02-25 | Davidson Michael H. | Chief Executive Officer | Open market sale | 1,300 | $36.68 |
| 2026-02-24 | Davidson Michael H. | Chief Executive Officer | Option exercise | 64,708 | — |
| 2026-02-24 | Davidson Michael H. | Chief Executive Officer | Open market sale | 61,547 | $36.13 |
| 2026-02-24 | Davidson Michael H. | Chief Executive Officer | Open market sale | 3,161 | $36.46 |
| 2026-02-20 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 14,692 | $35.00 |
| 2026-02-20 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Open market sale | 30,789 | $35.46 |
| 2026-01-28 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 32,612 | $10.90 |
| 2026-01-28 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 32,612 | $31.80 |
| 2026-01-27 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 39,816 | $10.90 |
| 2026-01-27 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 39,816 | $32.62 |
| 2026-01-26 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 34,400 | $10.90 |
| 2026-01-26 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 34,091 | $32.77 |
| 2026-01-26 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 309 | $33.45 |
| 2026-01-23 | Kooij Louise Frederika | Chief Accounting Officer | Option exercise | 38,172 | $10.90 |
| 2026-01-23 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 25,405 | $33.44 |
| 2026-01-23 | Kooij Louise Frederika | Chief Accounting Officer | Open market sale | 12,767 | $34.37 |
| 2026-01-21 | Somaiya Mayur Ian | Chief Financial Officer | Option exercise | 39,784 | $9.26 |
| 2026-01-21 | Somaiya Mayur Ian | Chief Financial Officer | Open market sale | 15,422 | $33.25 |
| 2026-01-21 | Somaiya Mayur Ian | Chief Financial Officer | Open market sale | 24,362 | $33.80 |
| 2026-01-20 | Somaiya Mayur Ian | Chief Financial Officer | Option exercise | 60,216 | $9.26 |
| 2026-01-20 | Somaiya Mayur Ian | Chief Financial Officer | Open market sale | 900 | $30.64 |
| 2026-01-20 | Somaiya Mayur Ian | Chief Financial Officer | Open market sale | 39,712 | $31.78 |
| 2026-01-20 | Somaiya Mayur Ian | Chief Financial Officer | Open market sale | 19,604 | $32.38 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:25 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-21 | 8-K | 2026-09-21 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-24 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-24 | 8-K | 2026-07-24 | View on SEC.gov → |
| 2026-07-22 | 8-K | 2026-07-16 | View on SEC.gov → |
Recent news
Headlines about NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares). Links open the publisher — we don’t host full articles.
-
NAMS Feb 2027 45.000 put (NAMS270219P00045000) interactive stock chart
Yahoo Finance UK · 2026-10-17 -
NAMS Nov 2026 30.000 put (NAMS261120P00030000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-17 -
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
Yahoo · 2026-10-13 -
Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3
Seeking Alpha · 2026-10-13 -
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
Yahoo Finance · 2026-10-02 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance · 2026-10-02 -
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
Yahoo Finance · 2026-09-29 -
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
Yahoo Finance · 2026-09-23
No headlines in this category right now — try “All”.